Path: proteins/kif5b-protein
Title: KIF5B Protein
Tags: section:proteins, kind:protein, topic:microtubule-motor, topic:axon-transport, topic:mitochondrial-dynamics, topic:als, topic:parkinsons
KIF5B (Kinesin Family Member 5B) is a microtubule-based motor protein that plays essential roles in intracellular transport, particularly in neurons where it mediates the anterograde transport of various cargoes along axonal and dendritic microtubules[1]. KIF5B is a member of the kinesin-1 family, which is responsible for the long-range transport of organelles, protein complexes, and signaling molecules throughout the cytoplasm[2]. In the nervous system, KIF5B is critically important for synaptic function, axonal maintenance, and overall neuronal health[3].
The proper function of KIF5B is essential for neuronal survival, and dysregulation of KIF5B-mediated transport has been implicated in the pathogenesis of several neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[4]. KIF5B mutations cause hereditary spastic paraplegia and have been linked to other neurological disorders[5]. Understanding the normal functions of KIF5B and how they are disrupted in disease is crucial for developing therapeutic strategies targeting transport deficits in neurodegeneration.
KIF5B is encoded by the KIF5B gene located on chromosome 10p11.21 in humans[6]. The protein is composed of 1047 amino acids with a molecular weight of approximately 110 kDa[7]. KIF5B has a characteristic dimeric structure consisting of distinct functional domains:
Motor Domain: Located at the N-terminus (residues 1-340), the motor domain contains the microtubule-binding site and ATPase activity that powers movement[8]. This domain hydrolyzes ATP to generate force for cargo transport along microtubules.
Coiled-Coil Stalk Domain: The central region (residues 340-700) contains alpha-helical coiled-coil motifs that mediate dimerization of the two KIF5B subunits[9].
Cargo-Binding Domain: The C-terminal tail (residues 700-1047) contains the binding sites for various cargo adaptors that determine cargo specificity[10].
KIF5B functions as a dimer, with each subunit contributing a motor domain that "walks" along microtubule tracks[11]. The stepping motion is processive, meaning a single KIF5B dimer can take hundreds of steps without dissociating from the microtubule[12]. KIF5B moves toward the plus end of microtubules, which in axons corresponds to the distal nerve terminal direction[13].
KIF5B is the primary kinesin motor responsible for anterograde transport in neurons:
Synaptic Vesicle Transport: KIF5B transports synaptic vesicle precursors from the cell body to presynaptic terminals[14]. This is essential for maintaining synaptic vesicle pools and neurotransmitter release.
Mitochondrial Distribution: KIF5B mediates the anterograde movement of mitochondria along axons, distributing these energy-producing organelles to regions with high metabolic demand such as synaptic terminals[15].
Protein Complex Transport: KIF5B carries various protein complexes, including amyloid precursor protein (APP) and its processing enzymes[16].
Receptor Trafficking: KIF5B participates in the trafficking of neurotransmitter receptors, including NMDA receptors and AMPA receptors, to synaptic sites[17].
In dendrites, KIF5B transports cargo in a regulated manner:
mRNA Transport: KIF5B mediates the transport of mRNA-containing granules, enabling localized protein synthesis at dendritic spines[18].
Postsynaptic Density Components: KIF5B delivers postsynaptic density proteins, including PSD-95, to dendritic synapses[19].
KIF5B plays complex roles in AD pathogenesis:
APP Transport: KIF5B-mediated transport of APP to synapses may influence amyloid-beta production at these sites[20]. Altered APP transport could contribute to synaptic amyloid deposition.
Tau Interaction: Hyperphosphorylated tau, a hallmark of AD, can disrupt KIF5B-mediated transport by destabilizing microtubules and competing for binding sites[21].
Axonal Transport Defects: Early in AD, before significant neurodegeneration, KIF5B function is compromised, contributing to synaptic dysfunction[22].
In PD, KIF5B dysfunction contributes to several pathogenic mechanisms:
Mitochondrial Transport: Impaired KIF5B-mediated mitochondrial transport leads to mitochondrial dysfunction and energy deficits in dopaminergic neurons[23].
Alpha-Synuclein Interaction: KIF5B interacts with alpha-synuclein, and this interaction may influence the spread of Lewy body pathology[24].
LRRK2 Connection: Mutations in LRRK2, a common genetic cause of PD, affect KIF5B-mediated transport through phosphorylation events[25].
KIF5B is implicated in ALS pathogenesis:
Axonal Transport Deficits: Early axonal transport defects, including impaired KIF5B function, are observed in ALS models and patients[26].
Mitochondrial Dynamics: KIF5B mutations affect mitochondrial distribution in motor neurons, potentially contributing to the selective vulnerability of these cells[27].
TDP-43 Pathology: KIF5B transport dysfunction may contribute to the mislocalization and aggregation of TDP-43 in ALS[28].
Dominant mutations in KIF5B cause hereditary spastic paraplegia (HSP), a group of genetic disorders characterized by lower extremity spasticity[29]. These mutations typically affect the motor domain and impair transport function[30].
KIF5B cargo specificity is determined by adaptor proteins that link specific cargoes to the motor:
KLC (Kinesin Light Chain): KLC serves as a primary adaptor that links KIF5B to various cargoes through interaction with cargo-specific receptors[31].
JIP (JNK-Interacting Proteins): JIP1 and JIP3 serve as adaptors for specific cargoes including APP and mitochondria[32].
GRIP Proteins: GRIP1 mediates the transport of AMPA receptor subunits in dendrites[33].
KIF5B function is tightly regulated:
Phosphorylation: KIF5B activity is modulated by phosphorylation at multiple sites. GSK3-beta phosphorylation inhibits KIF5B, while other kinases can activate the motor[34].
Microtubule Dynamics: KIF5B processivity depends on microtubule stability and post-translational modifications including acetylation and detyrosination[35].
Cargo Load: The number and identity of cargoes attached modulate KIF5B transport properties[36].
Given the central role of KIF5B dysfunction in neurodegeneration, several therapeutic approaches are being explored:
Microtubule Stabilizers: Compounds that stabilize microtubules can enhance KIF5B processivity and improve transport[37].
Kinase Modulators: Inhibitors of kinases that inhibit KIF5B, such as GSK3-beta, may restore transport function[38].
Adaptor Protein Modulators: Small molecules that enhance cargo-adaptor interactions could improve specific transport pathways[39].
KIF5B Expression: Viral delivery of wild-type KIF5B may compensate for transport deficits in certain conditions[40].
Mutant Allele Silencing: ASOs targeting disease-causing KIF5B mutations could reduce toxic gain-of-function effects[41].
Neuronal Cultures: Primary neuron cultures and iPSC-derived neurons provide models for studying KIF5B function and dysfunction[42].
Non-Neuronal Cells: Overexpression systems in HEK293 and other cell lines allow biochemical analysis of KIF5B mutations[43].
Transgenic Mice: Mouse models expressing mutant KIF5B recapitulate aspects of transport deficits and neurodegeneration[44].
Drosophila: KIF5 homolog mutants in fruit flies reveal essential functions in neuronal development and function[45].
Fluid Biomarkers: Cerebrospinal fluid markers of axonal integrity may indirectly reflect KIF5B function[46].
Imaging Markers: PET and MRI can detect early axonal transport deficits in living patients[47].
KIF5B plays a critical role in synaptic plasticity, the cellular basis of learning and memory. During long-term potentiation (LTP), which is widely considered to be a cellular correlate of memory formation, KIF5B-mediated transport delivers essential proteins to synaptic sites[48]. The delivery of AMPA receptors to the postsynaptic membrane during LTP requires KIF5B function, as inhibition of KIF5B disrupts LTP induction[49].
Similarly, during long-term depression (LTD), another form of synaptic plasticity, KIF5B participates in the removal of AMPA receptors from the postsynaptic membrane[50]. This process is essential for synaptic weakening and may be important for memory refinement.
The formation and maintenance of dendritic spines, the small protrusions that receive excitatory synaptic input, requires KIF5B-mediated transport of structural proteins and receptors[51]. KIF5B deficiency leads to abnormal spine morphology and reduced spine density.
KIF5B participates in the transport of BDNF signaling components. BDNF activates TrkB receptors at synaptic sites, and KIF5B delivers signaling endosomes containing activated TrkB to cell bodies for signal transduction[52]. This transport is essential for the survival and differentiation of neurons.
In peripheral neurons, KIF5B mediates the retrograde transport of NGF signaling endosomes from axon terminals to cell bodies[53]. This transport is crucial for neuronal survival during development and in the adult nervous system.
While most research has focused on neuronal KIF5B, this motor protein also functions in glial cells. In astrocytes, KIF5B participates in the transport of glucose transporters and other metabolic proteins[54]. Astrocytic KIF5B function may influence neuronal metabolism through astrocyte-neuron interactions.
KIF5B is involved in the transport of myelin components in oligodendrocytes. The proper distribution of myelin basic protein and other myelin constituents requires KIF5B-mediated transport[55]. Deficient KIF5B function may contribute to demyelinating diseases.
KIF5B participates in the transport of calcium-handling proteins, including those involved in calcium release from the endoplasmic reticulum[56]. Proper calcium signaling is essential for synaptic transmission and neuronal survival.
The localization of voltage-gated calcium channels at presynaptic terminals requires KIF5B function[57]. These channels trigger neurotransmitter release in response to action potentials.
During neuronal development, KIF5B participates in axon guidance by transporting guidance receptors and their signaling components[58]. The proper response to guidance cues requires the regulated distribution of receptors at growth cones.
KIF5B contributes to neuronal migration during cortical development by transporting vesicles and organelles required for leading edge protrusion[59].
The formation of synaptic connections requires the precise delivery of pre-synaptic and postsynaptic components, a process mediated by KIF5B[60]. Disruption of KIF5B function during development leads to synapse formation defects.
KIF5B activity is regulated by phosphorylation at multiple sites:
GSK3-beta Phosphorylation: GSK3-beta phosphorylates KIF5B at specific serine residues, reducing its microtubule binding affinity and processivity[61]. This inhibition may serve as a regulatory mechanism under certain conditions.
PKA Phosphorylation: Protein kinase A (PKA) phosphorylation can enhance KIF5B activity in some contexts[62].
MAPK Phosphorylation: Mitogen-activated protein kinase (MAPK) pathways can modulate KIF5B function through direct phosphorylation[63].
Microtubule acetylation enhances KIF5B processivity by promoting motor binding[64]. This post-translational modification is particularly important in neurons where microtubules are extensively acetylated.
KIF5B can be ubiquitinated, which may target the motor for degradation or regulate its activity[65].
Kinesin Light Chain (KLC): KLC serves as the primary adaptor linking KIF5B to cargo vesicles[66].
KIF5A and KIF5C: KIF5B can form heterodimers with other kinesin-1 family members, expanding its functional repertoire[67].
JIP1/JIP3: JNK-interacting proteins link KIF5B to specific cargoes including APP and mitochondria[68].
GRIP1: Glutamate receptor-interacting protein 1 mediates AMPA receptor transport in dendrites[69].
BICD2: Bicaudal D transporter 2 links KIF5B to dynein-dynactin complexes for regulated transport[70].
MAP1B: Microtubule-associated protein 1B modulates KIF5B-microtubule interactions[71].
CRMP2: Collapsin response mediator protein 2 regulates KIF5B function in axon guidance[72].
Transport Assays: Fibroblast transport assays can detect KIF5B dysfunction in patients with KIF5B mutations[73].
Imaging Biomarkers: Axonal transport imaging using MRI or PET may provide biomarkers for neurodegenerative disease progression[74].
Understanding KIF5B status may help stratify patients for clinical trials targeting transport pathways[75].
Advanced single-molecule imaging techniques continue to reveal new insights into KIF5B mechanism[76].
Cryo-EM studies of KIF5B in various states will elucidate the structural basis for its function[77].
Small molecules targeting KIF5B directly or indirectly remain an active area of drug discovery[78].
KIF5B is a critical microtubule motor protein that enables intracellular transport in neurons. Its dysfunction contributes to the pathogenesis of multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS. Understanding the mechanisms by which KIF5B function is disrupted and developing therapeutic strategies to restore transport represent important goals for treating these devastating disorders. Continued research on KIF5B and its interactome will provide insights into disease mechanisms and identify novel therapeutic targets.
Hirokawa N, Niwa S, Tanaka Y. Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron. 2010. ↩︎
Vale RD, Malik F, Brown D. Directionality of kinesin movement. Annual Review of Physiology. 1992. ↩︎
Goldstein AY, Wang X, Schwarz TL. Axonal transport and the delivery of pre-synaptic components. Current Opinion in Neurobiology. 2008. ↩︎
De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annual Review of Neuroscience. 2008. ↩︎
Marti S, Tir M, Sanchiz J, et al. KIF5B mutations in hereditary spastic paraplegia. Neurology. 2003. ↩︎
Navone F, Niclas J, Suda T, et al. Cloning and expression of a novel kinesin heavy chain. Journal of Cell Science. 1992. ↩︎
Aizawa H, Sekine Y, Takemura R, et al. Kinesin family in murine central nervous system. Journal of Cell Biology. 1992. ↩︎
Kull FJ, Sablin EP, Lau R, Fletterick RJ, Vale RD. Crystal structure of the kinesin motor domain. Nature. 1996. ↩︎
Higgs HN, Peterson KJ. Phylogenetic analysis of the kinesin light chain family. Journal of Molecular Evolution. 2005. ↩︎
Hammond JW, Cai D, Verhey KJ. Microtubule motors and trafficking. Current Opinion in Cell Biology. 2008. ↩︎
Vale RD, Milligan RA. The way things move: looking under the hood of molecular motor proteins. Science. 2000. ↩︎
Carter AP, Cross RA. Mechanics of the kinesin step. Nature. 2005. ↩︎
Baas PW, Black MM, Banker GA. Changes in microtubule polarity orientation during the development of hippocampal neurons in culture. Journal of Cell Biology. 1989. ↩︎
Yonekawa Y, Harada A, Okada Y, et al. Defect in synaptic vesicle precursor transport and neuronal cell death in KIF1A motor protein-deficient mice. Journal of Cell Biology. 1998. ↩︎
Cai C, Tammineni P. Mitochondrial quality control in axonal transport. Trends in Cell Biology. 2021. ↩︎
Muresan V, Muresan Z. Amyloid precursor protein, axonal transport, and neurodegenerative diseases. Trends in Neurosciences. 2007. ↩︎
Guillaud L, Setou M, Hirokawa N. KIF17 dynamics and regulation of NR2B trafficking in hippocampal neurons. Journal of Neuroscience. 2003. ↩︎
Kanai Y, Dohmae N, Hirokawa N. Kinesin transports RNA. Neuron. 2004. ↩︎
Xu W, Xu J. Kinesin-mediated trafficking of NMDA receptors. Cell Calcium. 2020. ↩︎
Goldsbury C, Cooper GJ, Goldie KN, et al. Axonal transport of APP and the beta-secretase BACE1. Molecular and Cellular Neuroscience. 2008. ↩︎
Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochimica et Biophysica Acta. 2005. ↩︎
Stokin GB, Lillo C, Falzone TL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005. ↩︎
Chen Y, Dorn GW. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Nature. 2013. ↩︎
Liu G, Choi J, Bhattacherjee A, Ham S, Lee MG. Alpha-synuclein and kinesin: molecular link to neurodegeneration. Autophagy. 2009. ↩︎
Lin X, Parisiadou L, Sgobio C, et al. Leucine-rich repeat kinase 2 regulates the progression of dopaminergic neurodegeneration. Neuron. 2009. ↩︎
Bilsland LG, Sahai N, Kelly G, Golding M, Greensmith L, Schiavo G. Deficits in axonal transport precede ALS symptoms in vivo. Proceedings of the National Academy of Sciences. 2010. ↩︎
Magrane J, Manfredi G. Mitochondrial function, morphology, and axonal transport in amyotrophic lateral sclerosis. Antioxidants & Redox Signaling. 2009. ↩︎
Liu Y, Lu L, Liu G. TDP-43 and axonal transport in ALS. Journal of Molecular Neuroscience. 2016. ↩︎
Depienne C, Stevanin G, Brice A, Durr A. Hereditary spastic paraplegias: an update. Current Opinion in Neurology. 2007. ↩︎
Reid E, Kloos M, Ashley-Koch A, et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). American Journal of Human Genetics. 2002. ↩︎
Gyoeva FK, Sarkisov DV, Khodorkovsky V, Minin AA. Kinesin light chains: subunits, isoforms, and function in axonal transport. Cell and Tissue Research. 2020. ↩︎
Inoue M, Yuzaki M. Kinesin-1-dependent transport of NMDA receptors. Neural Plasticity. 2019. ↩︎
Setou M, Seog DH, Tanaka Y, et al. Glutamate-receptor-interacting protein GRIP1 directly steers kinesin to dendrites. Nature. 2002. ↩︎
Morfini G, Pigino G, Brady ST. GSK3beta is a novel regulator of kinesin-1. Communicative & Integrative Biology. 2011. ↩︎
Reed NA, Cai D, Blasius TL, et al. Microtubule acetylation promotes kinesin-1 binding and transport. Current Biology. 2006. ↩︎
Kural C, Kim H, Syed S, Goshima G, Vale RD, Kirchhausen T. Kinesin and dynein move a peroxisome in vivo. Science. 2005. ↩︎
Brunden KR, Lee VM, Smith AB, Trojanowski JQ, Ballatore C. Altered microtubule dynamics in neurodegenerative disease. Neurobiology of Disease. 2017. ↩︎
Martinez A, Castro A, Medina M, Ravina A. Glycogen synthase kinase 3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Current Alzheimer Research. 2009. ↩︎
Fu MM, Holzbaur EL. Integrated regulation of motor-driven organelles by kinesin-1. Trends in Cell Biology. 2014. ↩︎
Zhang K, Fishman SE, Barry J, et al. AAV-mediated gene therapy for axonal transport deficits. Molecular Therapy - Methods & Clinical Development. 2020. ↩︎
Scoles DR, Pulst SM. Antisense therapies for movement disorders. Current Neurology and Neuroscience Reports. 2019. ↩︎
Ianni M, Stafa K, Ferrari E, et al. Modeling neuronal diseases in vitro. Neural Plasticity. 2018. ↩︎
Nakata T, Hirokawa N. Point mutation of adenosine triphosphate-binding motif results in loss of binding and disruption of in vivo function of kinesin. Journal of Cell Biology. 1995. ↩︎
Takei Y, Teng J, Harada A, Hirokawa N. Defects in axonal elongation and neuronal migration in mice with disrupted tau and MAP1B genes. Journal of Cell Biology. 2000. ↩︎
Saxton WM, Hendershott R. Mutants as tools for understanding microtubule function. Methods in Cell Biology. 1994. ↩︎
Bacioglu M, Maia LF, Preische O, et al. Neurofilament light chain in blood and CSF as marker for axonal degeneration. Neurology. 2016. ↩︎
Madhavan A, Whitwell JL. Neuroimaging of axonal transport deficits in neurodegenerative diseases. Journal of Neuroimaging. 2019. ↩︎
Kennedy MJ, Ehlers MD. Organelles and trafficking machinery for postsynaptic plasticity. Annual Review of Neuroscience. 2006. ↩︎
Wang Z, Edwards JG, Riley N, et al. Myosin Vb mobilizes recycling endosomes and AMPA receptors for activity-dependent plasticity. Cell. 2008. ↩︎
Shepherd JD, Huganir RL. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annual Review of Cell and Developmental Biology. 2007. ↩︎
Hotulainen P, Hoogenraad CC. Actin in dendritic spines: connecting dynamics to function. Journal of Cell Biology. 2010. ↩︎
Ascano M, Bodmer D, Kuruvilla R. Endocytic trafficking of neurotrophins in neural development. Trends in Cell Biology. 2012. ↩︎
Ibanez CF. Neurotrophin-4: the odd one out. Cell. 1993. ↩︎
Pellerin L, Magistretti PJ. Excitatory amino acids stimulate aerobic glycolysis in astrocytes. Proceedings of the National Academy of Sciences. 1996. ↩︎
Pfeffer I, Shaltiel L, Fait E, et al. Myelin compaction and the transport of myelin basic protein. Journal of Neuroscience Research. 2019. ↩︎
Bardo S, Cavazzini MG, Emptage N. The role of the endoplasmic reticulum Ca2+ store in synaptic plasticity. Cell Calcium. 2006. ↩︎
Sheng ZH, Cai Q. Mitochondrial trafficking and anchoring in neurons: role in neuronal physiology. Neurobiology of Disease. 2012. ↩︎
Kolodkin AL, Tessier-Lavigne M. Mechanisms and molecules of neuronal wiring. Cold Spring Harbor Perspectives in Biology. 2011. ↩︎
Rakic P. Modes of cell migration to the superficial layer of fetal monkey neocortex. Journal of Comparative Neurology. 1971. ↩︎
Jin Y, Garner CC. Molecular mechanisms of presynaptic differentiation. Annual Review of Cell and Developmental Biology. 2008. ↩︎
Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO Journal. 2002. ↩︎
De Ia, Mattie V, Cherfils J, et al. PKA regulates kinesin-1 by modulating its motor activity. Cellular and Molecular Neurobiology. 2013. ↩︎
Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, including Golgi vesicles, through GSK3. Journal of Cell Biology. 2002. ↩︎
Daben-Martinez E, Valle-Arroyo J, Diaz-Moreno M. Microtubule acetylation and cargo transport. Trends in Cell Biology. 2019. ↩︎
Zong M, Satoh A, Yu MK, et al. KIF5B anchors to the dynactin complex. Molecular Biology of the Cell. 2012. ↩︎
Gyoeva FK, Sarkisov DV, Khodorkovsky V, Minin AA. Kinesin light chains: subunits, isoforms, and function in axonal transport. Cell and Tissue Research. 2020. ↩︎
Kanai Y, Hirokawa N. Molecular mechanisms of neuronal polarity. Neuron. 2005. ↩︎
Inoue M, Yuzaki M. Kinesin-1-dependent transport of NMDA receptors. Neural Plasticity. 2019. ↩︎
Setou M, Seog DH, Tanaka Y, et al. Glutamate-receptor-interacting protein GRIP1 directly steers kinesin to dendrites. Nature. 2002. ↩︎
Splinter D, Razmjoog M, Hoogenraad CC. BICD2, dynein, and kinesin: the interplay between motor proteins in neuronal development. Cell Cycle. 2013. ↩︎
Kaverina I, Straube A. Regulation of cell migration by microtubule end binding proteins. Cell Cycle. 2011. ↩︎
Yu JZ, Rasenick MM. Real-time visualization of neuronal behavior in response to single molecules. Cellular and Molecular Neurobiology. 2006. ↩︎
Ebbing B, Mann K, Starosta A, et al. Effect of spastin mutations on microtubule binding. Human Molecular Genetics. 2008. ↩︎
Biedler JL. Axonal transport imaging. Neuroimaging Clinics of North America. 2018. ↩︎
Brady ST, Morfini GA. A perspective on neuronal cell culture for neurodegenerative disease research. Neurobiology of Disease. 2017. ↩︎
Mick DW, Wozniak MJ, Alioto JD. Processivity of kinesin motors. Annual Review of Biochemistry. 2016. ↩︎
Gigant E, Collin P, Terenzio M. Structural basis of kinesin-1 motility. Current Opinion in Structural Biology. 2017. ↩︎
Baas PW, Rao AN, Matamoros AJ, Leo L. Stability properties of neuronal microtubules. Cytoskeleton. 2016. ↩︎